Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.

@article{Pierga2012NeoadjuvantBT,
  title={Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study.},
  author={J. Y. Pierga and Thierry Petit and Thierry Delozier and J -M Ferrero and Mario Campone and Joseph Gligorov and Florence Lerebours and Henri Roch{\'e} and Thomas Bachelot and Emmanuelle Charafe-Jauffret and Maria Pavlyuk and Sandrine Kraemer and François-Cl{\'e}ment Bidard and Patrice Viens},
  journal={The Lancet. Oncology},
  year={2012},
  volume={13 4},
  pages={
          375-84
        }
}
BACKGROUND Bevacizumab and trastuzumab are efficacious for treatment of advanced or HER2-positive metastatic breast cancer; however, few data exist for this regimen in inflammatory breast cancer. In our phase 2 trial, we aimed to assess efficacy and safety of neoadjuvant bevacizumab combined with trastuzumab and chemotherapy in patients with primary HER2-positive inflammatory breast cancer. METHODS In our phase 2, multicentre, open-label, single-arm, non-comparative trial, we enrolled women… CONTINUE READING
Highly Cited
This paper has 77 citations. REVIEW CITATIONS
Tweets
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 58 citations

77 Citations

01020'13'15'17'19
Citations per Year
Semantic Scholar estimates that this publication has 77 citations based on the available data.

See our FAQ for additional information.

References

Publications referenced by this paper.
Showing 1-10 of 49 references